Baseline Characteristics
| Eyes treated with 0.2 µg/day FAc intravitreal implant (n=15 patients/19 eyes) | |
| Age (years), mean±SD | 64.7±14.08 |
| Males, % | 66.7 |
| Race, % | |
| Caucasian | 26.7 |
| Black/African American | 40.0 |
| Asian/Middle East Indian | 13.3 |
| Latino | 13.3 |
| Native Hawaiian | 6.7 |
| Type 2 diabetes, % | 93.3 |
| Diagnosis (years) before FAc, mean | |
| DME (n=19 eyes) | 2.90±2.45 |
| HbA1C, mean (%) | 7.07 |
| Initial lens status—Phakic %/Pseudophakic % (n=19 eyes) | 42.1/57.9 |
| Follow-up time (days)—Prior to FAc/After FAc administration | 872.7±601.8/399.3±222.91 |
FAc, fluocinolone acetonide.